Below are the most recent publications written about "Leukemia, Myeloid, Acute" by people in Profiles.
-
Pasricha TS, Abraczinskas D. Gastrointestinal Myeloid Sarcoma. N Engl J Med. 2020 Aug 27; 383(9):858.
-
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 08 13; 383(7):617-629.
-
Johansson KA, Økland JM, Skaftun EK, Bukhman G, Norheim OF, Coates MM, Haaland ØA. Estimating Health Adjusted Age at Death (HAAD). PLoS One. 2020; 15(7):e0235955.
-
Olsen SN, Armstrong SA. It's Not What You Say But How You Say It: Targeting RNA Methylation in AML. Mol Cell. 2020 06 18; 78(6):996-998.
-
Sahu KK, Sahu SA, Nageshwar P. Temporal region myeloid sarcoma: When to suspect and how to approach? Oral Maxillofac Surg. 2020 09; 24(3):369-370.
-
Lenard A, Xie HM, Pastuer T, Shank T, Libbrecht C, Kingsley M, Riedel SS, Yuan ZF, Zhu N, Neff T, Bernt KM. Epigenetic regulation of protein translation in KMT2A-rearranged AML. Exp Hematol. 2020 05; 85:57-69.
-
Rogers HJ, Wang X, Xie Y, Davis AR, Thakral B, Wang SA, Borthakur G, Cantu MD, Margolskee EM, Philip JKS, Sukhanova M, Bagg A, Bueso-Ramos CE, Orazi A, Arber DA, Hsi ED, Hasserjian RP. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. Am J Hematol. 2020 07; 95(7):799-808.
-
Cabal-Hierro L, van Galen P, Prado MA, Higby KJ, Togami K, Mowery CT, Paulo JA, Xie Y, Cejas P, Furusawa T, Bustin M, Long HW, Sykes DB, Gygi SP, Finley D, Bernstein BE, Lane AA. Chromatin accessibility promotes hematopoietic and leukemia stem cell activity. Nat Commun. 2020 03 16; 11(1):1406.
-
Wolach O, Stone RM. Optimal therapeutic strategies for mixed phenotype acute leukemia. Curr Opin Hematol. 2020 Mar; 27(2):95-102.
-
Brunner AM. The highs and lows of venetoclax with hypomethylating agents for refractory AML. Leuk Res. 2020 04; 91:106320.